Switching From Reference to Biosimilar Insulin Aspart for Patients With Diabetes Mellitus (Type 1 or Type 2)


( Last Updated : November 17, 2021)
Project Line:
Health Technology Review
Project Sub Line:
Summary of Abstracts
Project Number:
RB1600-000

Details


Question

  1. What is the clinical effectiveness of switching from reference to biosimilar insulin aspart in adult or pediatric patients with diabetes mellitus (Type 1 or Type 2)?

Key Message

Two randomized controlled trials were identified regarding the clinical effectiveness of switching from reference to biosimilar insulin aspart in adult or pediatric patients with diabetes mellitus (Type 1 or Type 2).